Skip to main content
SpringerLink
Log in

Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Colin PJ, Jonckheere S, Struys MMRF. Target-controlled continuous infusion for antibiotic dosing: Proof-of-principle in an in silico vancomycin trial in intensive care unit patients. Clin Pharmacokinet. 2018;57:1435–47.

    Article  CAS  Google Scholar 

  2. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325–7.

    Article  Google Scholar 

  3. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98.

    Article  CAS  Google Scholar 

  4. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309–16.

    Article  Google Scholar 

  5. Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54:318–23.

    Article  CAS  Google Scholar 

  6. Zeitlinger MA, Dehghanyar P, Mayer BX, Schenk BS, Neckel U, Heinz G, et al. Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother. 2003;47:3548–53.

    Article  CAS  Google Scholar 

  7. Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infect. 2019. https://doi.org/10.1016/j.cmi.2019.02.029.

    Article  PubMed  Google Scholar 

  8. Abrantes JA, Jönsson S, Karlsson MO, Nielsen EI. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019. https://doi.org/10.1111/bcp.13901.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wicha SG, Hennig S. Handling inter-occasion variability in model implementation for Bayesian forecasting: a comparison of methods and metrics [abstract no. 8580]. Annual Meeting of the Population Approach Group in Europe (PAGE); 2018. https://www.page-meeting.org/?abstract=8580. Accessed 20 Feb 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Iris K. Minichmayr & Markus Zeitlinger

  2. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

    Iris K. Minichmayr

Authors
  1. Iris K. Minichmayr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Zeitlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iris K. Minichmayr.

Ethics declarations

Funding

No funding was received for the preparation of this letter.

Conflict of interest

Iris K. Minichmayr and Markus Zeitlinger have no conflicts of interest that are directly relevant to the content of this article.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minichmayr, I.K., Zeitlinger, M. Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients”. Clin Pharmacokinet 58, 981–982 (2019). https://doi.org/10.1007/s40262-019-00768-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-019-00768-y

Search

Navigation